Effectiveness of COVID-19 Vaccines and Antiviral Therapies in the Era of SARS-CoV-2 Variants

Kalin Unuvar, Gamze; Rello, Jordi; Alp, Emine

doi:10.14744/etd.2022.99441

Effectiveness of COVID-19 Vaccines and Antiviral Therapies in the Era of SARS-CoV-2 Variants

Gamze KALIN ÜNÜVAR, (EEnfeksiyon Hastalıkları Departmanı, Erciyes Üniversitesi Tıp Fakültesi, Kayseri, Türkiye)

Jordi RELLO, (Yoğun Bakım Bölümü, Araştırma Merkezi Biomedica en Red (CIBERES), Vall d'Hebron Hastanesi Kampüsü, Barselona, İspanya)

Emine ALP (Bulaşıcı Hastalıklar Bölümü, Yıldırım Beyazıt Üniversite Tıp Fakültesi, Ankara, Türkiye)

Erciyes Medical Journal

3 2

Yıl: 2023 Cilt: 45 Sayı: 1 Sayfa Aralığı: 1 - 7 Metin Dili: İngilizce DOI: 10.14744/etd.2022.99441 İndeks Tarihi: 28-05-2023

Effectiveness of COVID-19 Vaccines and Antiviral Therapies in the Era of SARS-CoV-2 Variants

Öz:

Since December 2019, the respiratory infection coronavirus disease 2019 (COVID-19) has been responsible for a major pandemic. Several mutations and variants have emerged and been seen throughout the pandemic. They eventually spread to various continents and nations. The most effective method of preventing illnesses from the past till the present has been vaccination. As a result of the advancement of vaccinations, numerous nations have begun immunizing global target groups. From the start of COVID-19 to the present, there aren’t many possibilities for therapy. Data indicate that the rapid evolution and transmission of SARS-CoV-2 variants poses a danger to the effectiveness of currently available medications. As a result, the COVID-19 pandemic brought to light a serious public health issue that had an impact on everyone in the world. Along with the pandemic’s rapid speed, new targeted vaccinations and medical therapies have reduced fears to some extent. Clini- cal phase studies are still being conducted in various areas because it is evident that the initial antiviral medications approved for use in the treatment of COVID-19 are ineffective in severe cases. Anti-vaccination, however, is one of the most serious barriers to vaccination, which is thought to be vital in the prevention of illnesses. Lack of information, incorrect information, and misguided religious beliefs can all contribute to anti-vaccination. With the advent of SARS-CoV-2 variants, we review the literature to provide an up-to-date overview of the features and efficacy of antiviral therapy and vaccines.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Com- paring COVID-19 vaccines for their characteristics, efficacy and ef- fectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect 2022; 28(2): 202–21.
2. Forchette L, Sebastian W, Liu T. A Comprehensive review of COVID-19 virology, vaccines, variants, and therapeutics. Curr Med Sci 2021; 41(6): 1037–51.
3. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronavi- ruses. J Adv Res 2020; 24: 91–8.
4. Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DDS, Mishra S, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science 2021; 372(6544): 815–21.
5. Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, ımmunogenicity and safety of COVID-19 vaccines: A systematic review and meta-anal- ysis. Front Immunol 2021; 12: 714170.
6. Wu K, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE, et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. N Engl J Med 2021; 384(15): 1468–70.
7. Zhou Y, Zhi H, Teng Y. The outbreak of SARS-CoV-2 Omicron lineag- es, immune escape and vaccine effectivity. J Med Virol. 2022 Sep 12. doi: 10.1002/jmv.28138. [Epub ahead of print].
8. New Covid Variant BA.4.6 Outcompeting dominant BA.5 across swath of U.S. for first time. Available from: URL: https://deadline. com/2022/08/new-covid-variant-ba-4-6-u-s-midwest-1235103594/. Accessed Sept 16, 2022.
9. Ciotti M, Ciccozzi M, Pieri M, Bernardini S. The COVID-19 pandemic: viral variants and vaccine efficacy. Crit Rev Clin Lab Sci 2022; 59(1): 66–75.
10. Jalkanen P, Kolehmainen P, Häkkinen HK, Huttunen M, Tähtinen PA, Lundberg R, et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat Commun 2021; 12(1): 3991.
11. COVID-19 vaccine tracker. 2022. Available from: URL: https://vac- lshtm.shinyapps.io/ncov_ vaccine_landscape/. Accessed Sept 16, 2022.
12. Mateus J, Dan JM, Zhang Z, Rydyznski Moderbacher C, Lammers M, Goodwin B, et al. Low-dose mRNA-1273 COVID-19 vaccine gen- erates durable memory enhanced by cross-reactive T cells. Science 2021; 374(6566): eabj9853.
13. Ciabattini A, Pastore G, Fiorino F, Polvere J, Lucchesi S, Pettini E, et al. Evidence of SARS-CoV-2-Specific memory B cells six months after vaccination with the BNT162b2 mRNA vaccine. Front Immunol 2021; 12: 740708.
14. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383: 2603–15.
15. Hung IFN, Poland GA. Single-dose Oxford-AstraZeneca COVID-19 vaccine followed by a 12-week booster. Lancet 2021; 397(10277): 854–5.
16. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med 2022; 386(16): 1532–46.
17. Altarawneh HN, Chemaitelly H, Hasan MR, Ayoub HH, Qassim S, Al- Mukdad S, et al. Protection against the omicron variant from previous SARS-CoV-2 infection. N Engl J Med 2022; 386(13): 1288–90.
18. Abu-Raddad LJ, Chemaitelly H, Butt AA; National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 vac- cine against the B.1.1.7 and B.1.351 Variants. N Engl J Med 2021; 385(2): 187–9.
19. Russia’s Sputnik V shot around 83% effective against delta variant, health minister says. Available from: URL: https://www.reuters. com/ business/ healthcare pharmaceuticals/ russias-sputnik-v-shotar- ound-83-effective-against-delta-variant-health-minister-2021- 08-11. Accessed Sep 16, 2022.
20. The Sinovac-CoronaVac COVID-19 vaccine: What you need to know. Available from: URL: https://www.who.int/news-room/feature-sto- ries/detail/the-sinovac-covid-19-vaccine-what-you-need-to-know. Ac- cessed Sep 16, 2022.
21. Supasa P, Zhou D, Dejnirattisai W, Liu C, Mentzer AJ, Ginn HM, et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convales- cent and vaccine sera. Cell 2021; 184(8): 2201–11.e7.
22. Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 Vaccine against omicron variant in South Africa. N Engl J Med 2022; 386(5): 494–6.
23. Thompson MG, Natarajan K, Irving SA, Rowley EA, Griggs EP, Gaglani M, et al. Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of del- ta and omicron variant predominance - VISION network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep 2022; 71(4): 139–45.
24. Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med 2021; 27(12): 2136–43.
25. Novavax announces COVID-19 vaccine booster data demonstrating four-fold increase in neutralizing antibody levels versus peak respons- es after primary vaccination. Available from: URL: https://ir.novavax. com/2021-08-05-Novavax-Announces-COVID19-Vaccine-Booster- Data-Demonstrating-Four-Fold-Increase-inNeutralizing-Antibody-Lev- els-Versus-Peak-Responses-AfterPrimary-Vaccination. Accessed Sep 16, 2022.
26. Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, Zhou D, Ginn HM, Selvaraj M, et al; OPTIC Consortium; ISARIC4C Consortium. Anti- body escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022; 185(14): 2422–33.
27. Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfiz- er-BioNTech Bivalent COVID-19 vaccines for use as a booster dose. Available from: URL: https://www.fda.gov/news-events/press-an- nouncements/coronavirus-covid-19-update-fda-authorizes-moder- na-pfizer-biontech-bivalent-covid-19-vaccines-use. Accessed Sep 10, 2022.
28. Kumar S, Chandele A, Sharma A. Current status of therapeutic mono- clonal antibodies against SARS-CoV-2. PLoS Pathog 2021; 17(9): e1009885.
29. Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NCJE, et al. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS- CoV-2. Antimicrob Agents Chemother 2021; 65(5): e02428–20.
30. Hasanoğlu İ, Güner R, Çelik İ, Kanat F, Batırel A, Telli GD, et al. Rem- desivir treatment for patients with moderate to severe COVID-19. Turk J Med Sci 2022; 52(4): 880–7.
31. Vangeel L, Chiu W, De Jonghe S, Maes P, Slechten B, Raymenants J, et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res 2022; 198: 105252.
32. Ullrich S, Ekanayake KB, Otting G, Nitsche C. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. Bioorg Med Chem Lett 2022; 62: 128629.
33. Ledford H. The next variant: three key questions about what’s after Omicron. Nature 2022; 603(7900): 212–3.
34. White KM, Rosales R, Yildiz S, Kehrer T, Miorin L, Moreno E, et al. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science. 2021 Feb 26; 371(6532): 926–31.
35. Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. Effect of Bamlanivimab as monotherapy or in combination with Etesevimab on viral load in patients with mild to moderate COVID-19: A random- ized clinical trial. JAMA 2021; 325(7): 632–44.
36. Regeneron Pharmaceuticals Inc. Fact sheet for health care providers: emergency use authorization (EUA) of casirivimab and imdevimab. Available from: URL: https://www.regeneron.com/downloads/treat- ment-covid19-eua-fact-sheet-for-patient.pdf. Accessed Sep 16, 2022.
37. Focosi D, Tuccori M. Prescription of anti-spike monoclonal antibod- ies in COVID-19 Patients with resistant SARS-CoV-2 variants in Italy. Pathogens 2022; 11(8): 823.
38. Tian D, Nie W, Sun Y, Ye Q. The epidemiological features of the SARS-CoV-2 omicron subvariant BA.5 and its evasion of the neutral- izing activity of vaccination and prior ınfection. Vaccines (Basel) 2022; 10(10): 1699.
39. Aw J, Seng JJB, Seah SSY, Low LL. COVID-19 vaccine hesitancy-a scoping review of literature in high-income countries. Vaccines (Basel) 2021; 9(8): 900.

APA	Kalin Unuvar G, Rello J, Alp E (2023). Effectiveness of COVID-19 Vaccines and Antiviral Therapies in the Era of SARS-CoV-2 Variants. , 1 - 7. 10.14744/etd.2022.99441
Chicago	Kalin Unuvar Gamze,Rello Jordi,Alp Emine Effectiveness of COVID-19 Vaccines and Antiviral Therapies in the Era of SARS-CoV-2 Variants. (2023): 1 - 7. 10.14744/etd.2022.99441
MLA	Kalin Unuvar Gamze,Rello Jordi,Alp Emine Effectiveness of COVID-19 Vaccines and Antiviral Therapies in the Era of SARS-CoV-2 Variants. , 2023, ss.1 - 7. 10.14744/etd.2022.99441
AMA	Kalin Unuvar G,Rello J,Alp E Effectiveness of COVID-19 Vaccines and Antiviral Therapies in the Era of SARS-CoV-2 Variants. . 2023; 1 - 7. 10.14744/etd.2022.99441
Vancouver	Kalin Unuvar G,Rello J,Alp E Effectiveness of COVID-19 Vaccines and Antiviral Therapies in the Era of SARS-CoV-2 Variants. . 2023; 1 - 7. 10.14744/etd.2022.99441
IEEE	Kalin Unuvar G,Rello J,Alp E "Effectiveness of COVID-19 Vaccines and Antiviral Therapies in the Era of SARS-CoV-2 Variants." , ss.1 - 7, 2023. 10.14744/etd.2022.99441
ISNAD	Kalin Unuvar, Gamze vd. "Effectiveness of COVID-19 Vaccines and Antiviral Therapies in the Era of SARS-CoV-2 Variants". (2023), 1-7. https://doi.org/10.14744/etd.2022.99441

APA	Kalin Unuvar G, Rello J, Alp E (2023). Effectiveness of COVID-19 Vaccines and Antiviral Therapies in the Era of SARS-CoV-2 Variants. Erciyes Medical Journal, 45(1), 1 - 7. 10.14744/etd.2022.99441
Chicago	Kalin Unuvar Gamze,Rello Jordi,Alp Emine Effectiveness of COVID-19 Vaccines and Antiviral Therapies in the Era of SARS-CoV-2 Variants. Erciyes Medical Journal 45, no.1 (2023): 1 - 7. 10.14744/etd.2022.99441
MLA	Kalin Unuvar Gamze,Rello Jordi,Alp Emine Effectiveness of COVID-19 Vaccines and Antiviral Therapies in the Era of SARS-CoV-2 Variants. Erciyes Medical Journal, vol.45, no.1, 2023, ss.1 - 7. 10.14744/etd.2022.99441
AMA	Kalin Unuvar G,Rello J,Alp E Effectiveness of COVID-19 Vaccines and Antiviral Therapies in the Era of SARS-CoV-2 Variants. Erciyes Medical Journal. 2023; 45(1): 1 - 7. 10.14744/etd.2022.99441
Vancouver	Kalin Unuvar G,Rello J,Alp E Effectiveness of COVID-19 Vaccines and Antiviral Therapies in the Era of SARS-CoV-2 Variants. Erciyes Medical Journal. 2023; 45(1): 1 - 7. 10.14744/etd.2022.99441
IEEE	Kalin Unuvar G,Rello J,Alp E "Effectiveness of COVID-19 Vaccines and Antiviral Therapies in the Era of SARS-CoV-2 Variants." Erciyes Medical Journal, 45, ss.1 - 7, 2023. 10.14744/etd.2022.99441
ISNAD	Kalin Unuvar, Gamze vd. "Effectiveness of COVID-19 Vaccines and Antiviral Therapies in the Era of SARS-CoV-2 Variants". Erciyes Medical Journal 45/1 (2023), 1-7. https://doi.org/10.14744/etd.2022.99441